Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Structural, biological, and pharmacological strategies for the inhibition of nerve growth factor.

Eibl JK, Strasser BC, Ross GM.

Neurochem Int. 2012 Dec;61(8):1266-75. doi: 10.1016/j.neuint.2012.10.008. Epub 2012 Oct 26. Review.

PMID:
23103525
2.

Targeting nerve growth factor in pain: what is the therapeutic potential?

Watson JJ, Allen SJ, Dawbarn D.

BioDrugs. 2008;22(6):349-59. doi: 10.2165/0063030-200822060-00002. Review.

PMID:
18998753
3.

Nerve growth factor-mediated regulation of pain signalling and proposed new intervention strategies in clinical pain management.

McKelvey L, Shorten GD, O'Keeffe GW.

J Neurochem. 2013 Feb;124(3):276-89. doi: 10.1111/jnc.12093. Review.

4.

Single cycle structure-based humanization of an anti-nerve growth factor therapeutic antibody.

Covaceuszach S, Marinelli S, Krastanova I, Ugolini G, Pavone F, Lamba D, Cattaneo A.

PLoS One. 2012;7(3):e32212. doi: 10.1371/journal.pone.0032212. Epub 2012 Mar 5.

5.

Antagonism of nerve growth factor-TrkA signaling and the relief of pain.

Mantyh PW, Koltzenburg M, Mendell LM, Tive L, Shelton DL.

Anesthesiology. 2011 Jul;115(1):189-204. doi: 10.1097/ALN.0b013e31821b1ac5.

6.
7.

Modulation of neurotrophin signaling by monoclonal antibodies.

Rosenthal A, Lin JC.

Handb Exp Pharmacol. 2014;220:497-512. doi: 10.1007/978-3-642-45106-5_19. Review.

PMID:
24668485
8.

Nerve growth factor and its monocyte receptors are affected in kidney disease.

Antonucci MT, Bonofiglio R, Papalia T, Caruso F, Caroleo MC, Mancuso D, Aloe L.

Nephron Clin Pract. 2009;111(1):c21-8. doi: 10.1159/000178819. Epub 2008 Dec 9.

PMID:
19169037
9.

Nerve growth factor: structure and function.

Wiesmann C, de Vos AM.

Cell Mol Life Sci. 2001 May;58(5-6):748-59. Review.

PMID:
11437236
10.

Novel class of pain drugs based on antagonism of NGF.

Hefti FF, Rosenthal A, Walicke PA, Wyatt S, Vergara G, Shelton DL, Davies AM.

Trends Pharmacol Sci. 2006 Feb;27(2):85-91. Epub 2005 Dec 27. Review.

PMID:
16376998
11.
12.

Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain.

Mousa SA, Cheppudira BP, Shaqura M, Fischer O, Hofmann J, Hellweg R, Schäfer M.

Brain. 2007 Feb;130(Pt 2):502-13. Epub 2006 Dec 2.

PMID:
17142830
13.
14.

The biological effects of endogenous nerve growth factor on adult sensory neurons revealed by a trkA-IgG fusion molecule.

McMahon SB, Bennett DL, Priestley JV, Shelton DL.

Nat Med. 1995 Aug;1(8):774-80.

PMID:
7585179
15.

Characterization of antiallodynic actions of ALE-0540, a novel nerve growth factor receptor antagonist, in the rat.

Owolabi JB, Rizkalla G, Tehim A, Ross GM, Riopelle RJ, Kamboj R, Ossipov M, Bian D, Wegert S, Porreca F, Lee DK.

J Pharmacol Exp Ther. 1999 Jun;289(3):1271-6.

16.

Nerve growth factor & TrkA as novel therapeutic targets in cancer.

Demir IE, Tieftrunk E, Schorn S, Friess H, Ceyhan GO.

Biochim Biophys Acta. 2016 Aug;1866(1):37-50. doi: 10.1016/j.bbcan.2016.05.003. Epub 2016 Jun 2. Review.

PMID:
27264679
17.

The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.

Ugolini G, Marinelli S, Covaceuszach S, Cattaneo A, Pavone F.

Proc Natl Acad Sci U S A. 2007 Feb 20;104(8):2985-90. Epub 2007 Feb 14.

18.

Nerve growth factor and nociception: from experimental embryology to new analgesic therapy.

Lewin GR, Lechner SG, Smith ES.

Handb Exp Pharmacol. 2014;220:251-82. doi: 10.1007/978-3-642-45106-5_10. Review.

PMID:
24668476
19.

Antibodies to nerve growth factor reverse established tactile allodynia in rodent models of neuropathic pain without tolerance.

Wild KD, Bian D, Zhu D, Davis J, Bannon AW, Zhang TJ, Louis JC.

J Pharmacol Exp Ther. 2007 Jul;322(1):282-7. Epub 2007 Apr 12.

20.

Supplemental Content

Support Center